Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Paul Dendale ,
Dr. Eugenio Greco,
The association of albuminuria and high-sensitivity C-reactive protein with the efficacy of HMG-coenzyme A reductase inhibitors for cardiovascular event prevention
Özyilmaz A. et al
European Journal of Preventive Cardiology, September 10, 2015, doi 20152047487315604310
In this study, the authors investigated whether subjects with hypercholesterolemia will benefit more from starting statin treatment in the case of high albuminuria and/or high-sensitivity C-reactive protein (hsCRP), because it is not clear which hypercholesterolemic patients benefit most from β-hydroxy-β-methylglutaryl coenzyme A reductase inhibitors with respect to the prevention of cardiovascular events.
The authors compared the data of 2011 subjects who had hypercholesterolemia at baseline, a negative cardiovascular disease history and who were not treated with statins: 695 subjects started with a statin during a follow-up of 7.0 ± 1.7 years.
Adjusted hazard ratios for cardiovascular events were calculated in subjects who started versus those who did not start a statin stratified for albuminuria less than or ≥ 15 mg/day and/or hsCRP less than or ≥ 3 mg/L.
The results were that the start of a statin was associated with a beneficial effect on cardiovascular risk in subjects with high albuminuria, while the effect of starting a statin was non-significant in subjects with low albuminuria.
The effect of starting a statin was similar in subgroups with high and low hsCRP.
When combining albuminuria and hsCRP subgroups, the start of statin treatment was associated with a lower risk of cardiovascular events dependent on albuminuria and not on the hsCRP level.
This is of course a post-hoc analysis of a non-randomised cohort, so any conclusions should be considered hypothesis generating. If proven correct, this would mean that patients that have already signs of vascular damage such as albuminuria have a stronger indication for statins.
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology
© 2017 European Society of Cardiology. All rights reserved